Fig. 1
Antitumor effects of SHR6390 in ESCC cell lines and xenografts. a SHR6390 showed inhibitory activity against ESCC cells with different drug susceptibility. Proliferation assay are expressed as the mean ± SD of three replicate assays. b In vivo antitumor activity of SHR6390 in subcutaneous Eca 109 cells line-derived xenografts. SHR6390 caused tumor regression in Eca 109 xenograft. c In vivo antitumor activity of SHR6390 in subcutaneous Eca 9706 cell line-derived xenografts. The growth of tumors treated with SHR6390 alone was significantly suppressed in the Eca 9706 xenograft. d–i Effects of SHR6390 on the ESCC PDXs models. Tumors subcutaneously engrafted and grown until 150–200 mm3. Then, mice were treated with 150 mg/kg SHR6390 for 21 days and tumors were measured twice daily. Compared to the control group, the growth of tumor was significantly suppressed in SHR6390 treatment group with various suppressions. Tumor volume was expressed as mean ± SD. The antitumor activity is depicted by % TGI. TGI = ΔT/ΔC × 100% (ΔT = tumor volume change of the drug-treated group, ΔC = tumor volume change of the control group on the final day of the study). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by one-way ANOVA or unpaired two-tailed t test